ArticleFrontiers in medicine2026
The predictive value of interleukin-2 receptor and prognostic nutritional index in patients with diffuse large B-cell lymphoma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), accounting for 30-40% of NHL cases. It exhibits high heterogeneity in gene expression and genetics, leading to significant variability in clinical treatment outcomes. Currently, various methods are available for predicting the prognosis of DLBCL patients, including the classic International Prognostic Index (IPI), as well as gene sequencing and circulating tumor DNA (ctDNA). However, some of these prognostic stratification methods are invasive and costly, limiting their widespread application. Therefore, there is an urgent need to identify potential prognostic indicators for lymphoma that can be widely used in the prognostic assessment of DLBCL patients, thereby further improving the stratification of DLBCL prognosis. Objective: This study aims to determine the prognostic value of serum interleukin-2 receptor (IL-2R) and prognostic nutritional index (PNI) in patients diagnosed with diffuse large B-cell lymphoma (DLBCL), as well as their applicability across different DLBCL subtypes. Methods: A retrospective analysis was conducted on 171 newly diagnosed DLBCL patients who received standard chemotherapy at Tongji Hospital in Shanghai from March 2013 to March 2024. Among them, 136 patients completed serum IL-2R testing. Spearman's correlation analysis was used to describe the associations between different categorical indicators. The optimal cutoff values were determined based on receiver operating characteristic (ROC) curves. Kaplan-Meier analysis and log-rank tests were employed to compare survival rates among different subgroups. Finally, univariate and multivariate Cox proportional hazards regression models were applied to identify factors influencing the prognosis of DLBCL patients. Results: The baseline levels of IL-2R were correlated with patient age, nutritional status, and inflammatory response. PNI was associated with tumor burden in patients. Among the 136 patients, the cutoff value for IL-2R was 1,202 U/mL, while the cutoff value for PNI in the 171 patients was 44.65. Patients with high IL-2R and low PNI shared common characteristics, including advanced age, higher Ann Arbor stage, more frequent B symptoms, higher IPI scores, a higher proportion of intermediate-to-high-risk patients, poorer performance status, and shorter overall survival (OS) and progression-free survival (PFS). Multivariate analysis indicated that IL-2R > 1,202 U/mL and PNI ≤ 44.65 were independent risk factors for poor PFS and OS in newly diagnosed DLBCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.